Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients.

Conclusion: This study provides evidence for alterations in gut-microbiota-derived SCFAs with advancing CKD, demonstrates the association of higher plasma valerate levels with pre-existing CVD, and reveals areas for future exploration of cardiovascular risk in patients with CKD. PMID: 30326477 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30326477?dopt=Abstract

Source: American Journal of Nephrology - October 16, 2018 Category: Urology & Nephrology Authors: Jadoon A, Mathew AV, Byun J, Gadegbeku CA, Gipson DS, Afshinnia F, Pennathur S, for the Michigan Kidney Translational Core CPROBE Investigator Group Tags: Am J Nephrol Source Type: research